News

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

This review of the latest dermatologic studies includes insights into erectile dysfunction in dermatology and venereology, diet and psoriasis information on TikTok, and more.

Catch up on coverage from the final day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Test your knowledge of key words and terms associated with dermatology meeting news from the previous week.

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Explore the top headlines of the week including insights on the environmental impact of conferences, new clinical data, and the shift towards more natural-looking results.

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Catch up on coverage from the third day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

Catch up on coverage from the second day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.